Investor event with a focus on opportunities within life science
NEWS. On November 9, 2023, Sciety invited its investor network to an exclusive event on the theme of future scenarios and opportunities within life science. The evening featured a panel discussion on data-driven precision medicine with Tommi Unkuri, Partner and Co-founder of Summa Equity; Mattias Häggblom, Sector Head for Healthcare, Equity Research at Handelsbanken; and Mats Nilsson, professor at Science for Life Laboratory (SciLifeLab) and Co-founder of several biotech companies including Olink.
Sciety invited its investor network to yet another successful edition of the recurring event “future scenarios and opportunities within life science”. Together with prominent researchers, leading investors, and industry analysts, we took a deep dive into cutting-edge research and explored the latest trends in life science and digital health – from an investor perspective.
Sciety was pleased to welcome an expert panel consisting of our board member Tommi Unkuri, Partner and Co-founder of Summa Equity, an impact-focused private equity firm that manages approx. SEK 40 billion, where he is responsible for healthcare and life science investments; Mattias Häggblom, Sector Head for Healthcare, Equity Research at Handelsbanken Capital Markets, and one of the leading market analysts within life science in the Nordics; and Mats Nilsson, Professor at Science for Life Laboratory (SciLifeLab) – a Swedish national science center for large-scale research in life sciences – and Co-founder of several biotech companies including Olink, Q-linea, Halo Genomics, EMPE Diagnostics and Cartana.
The main topic of the night was data-driven precision medicine – a fast-growing field which offers personalised care against complex diseases such as cancer, diabetes, and cardiovascular diseases. The theme was discussed from a researcher, investor and market perspective with leading sector experts who shared in-depth analysis and unique insights from their respective industries. Precision medicine has the potential to revolutionise the future of healthcare, and Sweden is at the forefront of that rapid development, where the power of data is being used to diagnose diseases and tailor treatments.
Gunnar Ahlberg, Venture Partner at Sciety and PhD surgeon with over 40 years of clinical and strategic experience in healthcare, introduced the audience to the evening’s theme from a medical and scientific viewpoint, and moderated the subsequent panel conversation on recent innovations and investment opportunities within precision medicine.
Andreas Lindblom, Managing Partner at Sciety, discussed upcoming projects and shared some exciting news about Sciety’s continued growth journey and vision ahead.
Sciety would like to take the opportunity to thank all speakers and participants and look forward to organising similar events in the future.
Andreas Lindblom, Managing Partner, Sciety: firstname.lastname@example.org, phone 070-375 73 73
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world. For more information, please visit www.sciety.com and follow us on LinkedIn.
Receive news and invitations from Sciety
Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.